1. Although Maxy-VII was the impetus for the deal, Bayer also acquired MAXY’s FVIII and FIX analogs, which are much earlier in development than Maxy-VII (i.e. not ready for human testing) and had not been previously disclosed.
2. With this deal, MAXY is completely out of the hematology arena and is focused entirely on autoimmune diseases.
3. The $30M milestone will be earned by MAXY when Maxy-VII enters phase-2 trials and patent coverage for the compound issues in the US and EU.
Market Data 
Markets 
AI
